NASDAQ
27.02.26 | 21:59
2,125 US-Dollar
-9,19 % -0,215
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Sa | ALX Oncology outlines pivotal trial readiness by end of 2026 with expanded ASPEN-09 study and $150M financing | 1 | Seeking Alpha | ||
| ALX ONCOLOGY Aktie jetzt für 0€ handeln | |||||
| Fr | ALX Oncology: Aktie fällt nach verfehlter Gewinnprognose für Q4 2025 | 2 | Investing.com Deutsch | ||
| Fr | ALX Oncology GAAP EPS of -$0.42 misses by $0.06 | 1 | Seeking Alpha | ||
| Fr | ALX Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update | 1.159 | GlobeNewswire (Europe) | - Clinical development for both the investigational CD47-inhibitor evorpacept and the novel EGFR-targeted antibody-drug conjugate ALX2004 remains on track following strong 2025 execution; company... ► Artikel lesen | |
| Fr | ALX ONCOLOGY HOLDINGS INC - 8-K, Current Report | 5 | SEC Filings | ||
| Do | A Look Ahead: ALX Oncology Holdings' Earnings Forecast | 1 | Benzinga.com | ||
| 19.02. | ALX Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026 | 2 | GlobeNewswire (USA) | ||
| 02.02. | ALX Oncology Prices $150 Mln Offering Of Shares And Pre-funded Warrants | 3 | RTTNews | ||
| 30.01. | ALX Oncology announces pricing of underwritten offering; shares up nearly 15% | 2 | Seeking Alpha | ||
| 30.01. | ALX Oncology platziert Kapitalerhöhung über 150 Mio. US-Dollar zu 1,57 US-Dollar je Aktie | 2 | Investing.com Deutsch | ||
| 30.01. | ALX Oncology prices $150 million stock offering at $1.57 per share | 3 | Investing.com | ||
| 30.01. | ALX Oncology reports CD47 biomarker findings in breast cancer trial | 2 | Investing.com | ||
| 30.01. | ALX Oncology: CD47-Biomarker könnte Therapieerfolg bei Brustkrebs vorhersagen | 7 | Investing.com Deutsch | ||
| 30.01. | ALX ONCOLOGY HOLDINGS INC - 8-K, Current Report | 2 | SEC Filings | ||
| 30.01. | New Data Demonstrate CD47 Expression Level Helps Predict Response to ALX Oncology's Evorpacept in Combination with Ziihera (zanidatamab-hrii) in Advanced HER2-Positive Breast Cancer | 2 | GlobeNewswire (USA) | ||
| 21.01. | ALX Oncology stockt Aktienprogramm für neue Mitarbeiter auf | 4 | Investing.com Deutsch | ||
| 21.01. | ALX ONCOLOGY HOLDINGS INC - S-8, Securities to be offered to employees in employee benefit plans | 3 | SEC Filings | ||
| 21.01. | ALX ONCOLOGY HOLDINGS INC - 8-K, Current Report | 1 | SEC Filings | ||
| 08.01. | ALX Oncology Advances Separate Clinical Trials Evaluating Investigational CD47-Inhibitor Evorpacept and Novel EGFR-Targeted Antibody-Drug Conjugate ALX2004 | 128 | GlobeNewswire (Europe) | - First patient dosed in Phase 2 ASPEN-09-Breast trial evaluating evorpacept in combination with trastuzumab and physician's choice of chemotherapy in HER2-positive metastatic breast cancer; interim... ► Artikel lesen | |
| 08.12.25 | ALXO Presents Phase 2 Data Of Evorpacept In Frontline Indolent Non-Hodgkin Lymphoma At The ASH | 1 | RTTNews |
1 2 3 Weiter >>
44 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 5,880 | +0,38 % | Evotec: Das Biotech-Drama geht in die nächste Runde | Die Aktie des Hamburger Wirkstoffforschers Evotec versucht erneut den Befreiungsschlag, doch das Misstrauen am Markt ist greifbar. Nach einer beispiellosen Serie von Rückschlägen - von Management-Skandalen... ► Artikel lesen | |
| MODERNA | 45,160 | -0,41 % | Aufgrund von angeblichen Patentverletzungen zieht BioNTech gegen Moderna vor Gericht | Die Hersteller von Corona-Impfstoffen haben sich schon seit Jahren in den Haaren. Immer wieder gibt es Vorwürfe über Patentverletzungen. So auch in einem aktuellen Fall, bei dem BioNTech gegen den US-Hersteller... ► Artikel lesen | |
| NOVAVAX | 8,495 | -0,97 % | FOMO an der Wall Street: Novavax meldet überraschenden Gewinn - Aktie schießt zweistellig hoch | © Foto: picture alliance / Ulrich Baumgarten | Ulrich BaumgartenEin Ergebnis, das niemand erwartet hatte, gepaart mit neuen Big-Pharma-Deals: Novavax sorgt für FOMO an der Wall Street. Wie lange hält... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 50,50 | -0,98 % | Crispr Therapeutics gains amid takeover speculation | ||
| INOVIO PHARMACEUTICALS | 1,500 | -2,60 % | Is Inovio Pharmaceuticals Stock Going to $0? | ||
| INTELLIA THERAPEUTICS | 11,645 | -0,13 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates |
HAELO Phase 3 clinical data for lonvo-z in HAE expected by mid-2026; BLA submission in second half of 2026; anticipated U.S. launch in first half of 2027Process underway to reactivate global sites... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,371 | -1,85 % | Defence Therapeutics Inc.: Defence Therapeutics Announces Private Placement of Units for Proceeds of up to $11 Million | Montreal, Quebec--(Newsfile Corp. - February 27, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology and precision... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 52,88 | +1,23 % | FDA Expands BioMarin's PALYNZIQ Approval To Include Pediatric PKU Patients Ages 12 And Up | WASHINGTON (dpa-AFX) - BioMarin Pharmaceutical Inc. (BMRN) announced Friday that the U.S. Food and Drug Administration has approved the company's supplemental Biologics License Application for... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 14,155 | -0,18 % | Sarepta Therapeutics Stock: A Deep Dive Into Analyst Perspectives (5 Ratings) | ||
| EXELIXIS | 37,260 | -0,11 % | 3 Reasons Exelixis Stock Could Deliver Market-Beating Returns Over the Next Decade | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,438 | +0,86 % | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. - S-8, Securities to be offered to employees in employee benefit plans | ||
| HALOZYME THERAPEUTICS | 59,08 | +0,37 % | Halozyme Therapeutics, Inc.: Halozyme Reports Full Year 2025 Record Revenue Of $1.4 Billion And Reiterates Strong 2026 Financial Guidance | Full Year 2025 Total Revenue Increased 38% YOY to Record $1.397 billionFull Year 2025 Royalty Revenue Increased 52% YOY to Record $868 million
Completed Acquisitions... ► Artikel lesen | |
| NEUROCRINE BIOSCIENCES | 111,70 | 0,00 % | Wolfe Research startet Neurocrine-Aktie mit "Outperform" - Starke Medikamenten-Pipeline als Kurstreiber | ||
| VAXART | 0,630 | 0,00 % | Vaxart, Inc.: Vaxart Provides Business Update and Reports Third Quarter 2025 Financial Results | Entered into an exclusive license agreement with Dynavax for the Company's COVID-19 oral pill vaccine candidate for potential cumulative proceeds of up to $700 million plus royalties Completed enrollment... ► Artikel lesen |
ALX ONCOLOGY HOLDINGS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,215 (-9,19 %) liegt der Kurs bei 2,125 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ALX ONCOLOGY HOLDINGS INC finden Sie auf Wallstreet Online.